Global Short Bowel Syndrome (SBS) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Short Bowel Syndrome (SBS) Market Research Report 2024
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
According to MRAResearch’s new survey, global Short Bowel Syndrome (SBS) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Short Bowel Syndrome (SBS) market research.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Short Bowel Syndrome (SBS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Segment by Type
Oral Route
Parental Route
Segment by Sale Channel
Hospitals
Clinics
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Short Bowel Syndrome (SBS) report covers below items
Chapter 1Product Basic Information (Definition, Type and Sale Channel)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Sale Channel Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Short Bowel Syndrome (SBS) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Short Bowel Syndrome (SBS) market research.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Short Bowel Syndrome (SBS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Segment by Type
Oral Route
Parental Route
Segment by Sale Channel
Hospitals
Clinics
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Short Bowel Syndrome (SBS) report covers below items
Chapter 1Product Basic Information (Definition, Type and Sale Channel)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Sale Channel Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source